0
0
A groundbreaking 13-year study has confirmed that gene therapy can dramatically reduce bleeding episodes and the need for regular medication in patients with severe hemophilia B, marking a major advance in the treatment of this rare genetic disorder.
Hemophilia B and Its Challenges
Hemophilia B is a rare bleeding disorder caused by mutations in the F9 gene, resulting in a deficiency of factor IX, a protein essential for blood clotting. In the United States, about 7,000 individuals are affected. Those with severe hemophilia B have less than 1% of normal factor IX activity, often suffering from spontaneous bleeding that can cause joint damage or life-threatening events.
Standard treatment has involved lifelong infusions of factor IX concentrate, which, while effective, are expensive, invasive, and time-consuming.
AAV Gene Therapy: A One-Time Solution
Researchers from St. Jude Children’s Research Hospital and University College London tested an adeno-associated virus (AAV) gene therapy, delivering a working copy of the F9 gene directly into the liver. This approach enables the patient’s body to produce its own factor IX after a single intravenous dose.
Ten men with severe hemophilia B received the experimental therapy and were followed for 13 years. The study divided participants into low, intermediate, and high-dose groups based on the amount of viral particles administered per kilogram of body weight.
Dramatic and Durable Results
The results were striking:
-
The high-dose group maintained steady factor IX levels (about 4.8 IU/dL) for over a decade.
-
Median annual bleeding episodes dropped from 14 to 1.5, a 9.7-fold reduction; in the high-dose group, bleeding dropped 16.4-fold.
-
Seven out of ten participants no longer needed regular preventive treatment.
-
Factor IX concentrate use fell from a median of 2,613 IU/kg/year to 367 IU/kg/year overall, a 12.4-fold decrease; in the high-dose group, usage dropped to 171 IU/kg/year, a 14.7-fold reduction.
No participants developed antibodies against the therapy or experienced serious liver issues. Two participants developed cancer, but doctors concluded these cases were likely unrelated to the gene therapy.
Ongoing Questions and Future Directions
While the therapy’s safety profile remains strong, the study found that high levels of antibodies to the AAV virus persisted for years, which may limit the ability to repeat the treatment if needed. The authors emphasized the need for continued monitoring to evaluate rare risks and called for further research on gene expression durability and immune system challenges, since AAV gene therapy may remain a one-time treatment for most patients.
Disclaimer
This article is for informational purposes only and does not constitute medical advice. The findings discussed are based on a specific clinical study and may not apply to all patients. Individuals should consult healthcare professionals for personal medical guidance and before considering any new treatment options.
